• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Barbieri Allen gifted 23,000 shares, decreasing direct ownership by 23% to 78,337 units (SEC Form 5)

    7/3/24 5:10:23 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BMRA alert in real time by email
    SEC FORM 5 SEC Form 5
    FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0362
    Estimated average burden
    hours per response: 1.0
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Form 3 Holdings Reported.
      
    Form 4 Transactions Reported.
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BARBIERI ALLEN

    (Last) (First) (Middle)
    17571 VON KARMAN AVE

    (Street)
    IRVINE CA 92614

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIOMERICA INC [ BMRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Vice Chairman
    3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
    05/31/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Amount (A) or (D) Price
    Common Stock 06/27/2023 G 8,000(1) D $0.00 93,327 D
    Common Stock 01/02/2024 G 15,000(1) D $0.00 78,337 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This Form 5 reports two gifts of shares by the reporting person to nonprofit 501(c)(3) charitable organization.
    /s/ Allen Barbieri 07/03/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biomerica Inc.

      SC 13G/A - BIOMERICA INC (0000073290) (Subject)

      11/14/24 4:19:51 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Biomerica Inc. (Amendment)

      SC 13G/A - BIOMERICA INC (0000073290) (Subject)

      2/14/24 9:00:06 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Biomerica Inc.

      SC 13G - BIOMERICA INC (0000073290) (Subject)

      2/9/24 3:06:57 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System

      Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomesPrecision Medicine: inFoods® IBS identifies specific individual food triggers that can cause IBS symptoms (bloating, pain, diarrhea, and constipation) offering a personalized, non-drug solution IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today anno

      5/22/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement

      - Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the American Medical Association (AMA) CPT Editorial Panel requesting the assignment of a Proprietary Laboratory Analysis (PLA) code for the inFoods® IBS diagnostic test. If granted, the PLA

      5/7/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Detection of H. pylori Infection

      10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerApproximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogenThis test empowers healthcare providers with fast, accessible testing across the UAE IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced today that its Fortel® Ulcer Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory approval enables Biomerica to introduce its rapid point-of-care test for Heli

      4/23/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Emerson Jane was granted 85,000 shares, increasing direct ownership by 120% to 156,000 units (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:09 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Coste Catherine was granted 85,000 shares, increasing direct ownership by 194% to 128,790 units (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:05 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Moatazedi David was granted 85,000 shares (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:07 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    SEC Filings

    See more
    • Biomerica Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BIOMERICA INC (0000073290) (Filer)

      4/16/25 9:00:09 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Biomerica Inc.

      10-Q - BIOMERICA INC (0000073290) (Filer)

      4/14/25 4:15:33 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Biomerica Inc.

      10-Q - BIOMERICA INC (0000073290) (Filer)

      1/14/25 5:06:05 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Financials

    Live finance-specific insights

    See more

    $BMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

      InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting  Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs  Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q  Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products, today reported its second quarter fiscal 2023 fina

      1/13/23 6:39:00 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

      IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, "LabCorp" (NYSE:LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world's largest diagnostics clinical laboratories, boasting $7B in annual revenues, ov

      2/21/24 8:19:00 AM ET
      $BMRA
      $LH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Medical Specialities
    • Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica

      Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to serve as the Chairman of the Board of Directors of Biomerica. Mr. Zack Irani will continue to serve as CEO. Mr. Kenny joined the Biomerica Board of Director

      1/23/24 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Diagnostics Industry Leader Jack Kenny Joins Biomerica's Board of Directors

      Kenny has proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian BioscienceAs CEO Kenny managed the sale of Meridian Biosciences in an all-cash transaction valued at approximately $1.53 billion NEWPORT BEACH, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors. Meridian Biosciences (formerly traded on Nasdaq under VIVO) is a leadin

      8/28/23 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care